Home Blog Page 157

Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

By
Advertorial Desk
-

Results Highlights for Interim Results ended 30 June 2026
Revenue reached RMB1,006.5 million, increasing by 21.0% YoY
Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY
Gross profit margin was 34.0%

HONG KONG, Aug. 26, 2026 /PRNewswire/ — On August 26, 2026, Viva Biotech Holdings Group (“the Group” or “the Company”, stock code: 1873.HK) announced that the Group’s revenue amounted to RMB1,006.5 million and gross profit of RMB341.7 million, representing a gross margin of 34.0%. Overall, the Group’s total revenue grew by approximately 21.0% year-on-year, primarily driven by the significant contribution from Langhua Pharmaceutical’s CDMO business, under which one peptide project has entered the commercial production phase and the other small-molecule project has reached the PPQ phase. In addition, in the first half of 2026, the Group recorded a net profit of RMB100.9 million and an adjusted non-IFRS net profit of RMB128.3 million, both representing a decline compared with the corresponding period of last year. This was mainly attributable to a decrease in investment income contributions during the Reporting Period, unfavorable foreign exchange movements and increased R&D expenses associated with new business development.

CRO Revenue Growth Set for Recovery, with AI-Driven Drug R&D Leading a New Paradigm in Drug Discovery

In the first half of 2026, the Group’s CRO revenue amounted to RMB405.1 million; adjusted gross profit for the corresponding period reached RMB173.7 million. Backed by a strong order backlog and the ongoing expansion of AI and other new technology platforms, the Company is expected to maintain a full-year growth rate in 2026 at or above its current level.

The Group’s cumulative number of CRO clients increased to 1,984, including the top 10 global pharmaceutical companies, with the top 10 clients accounting for 26.6% of CRO revenue.

As of June 30, 2026, the Company had cumulatively delivered over 108,163 protein structures to clients, of which approximately 9,278 were newly delivered in the first half of 2026. Cumulatively, over 2,557 independent drug targets have been studied, with 212 newly delivered in the first half of 2026. The number of delivered independent drug targets grew markedly, driven by the rapid advancement of AI-powered drug discovery and the resulting surge in wet-lab demand. The Company continues to lead the industry globally in protein structure determination. New modality offerings, including peptides, antibodies, XDCs, and PROTACs/molecular glues, accounted for approximately 17.7% of total CRO revenue, representing a year-on-year increase of nearly 10.7%.

As of June 30, 2026, CADD/AIDD had cumulatively participated in 228 projects, with 92 cumulative clients having procured CADD/AIDD services. Revenue contribution from AI-empowered projects accounted for approximately 14.0% of total CRO revenue. A deep collaboration with a global industry leader advanced our AI-driven “dry-wet closed-loop” model, laying a foundation for future MNC partnerships. The CADD/AIDD team launched the MARS multimodal integrated algorithm platform, leveraging Pep2MARS to establish a strong competitive advantage in designing peptides, cyclic peptides, and complex macrocycles. Through the comprehensive upgrade of its three underlying modules, V-Scepter, V-Orb, and V-Mantle, the platform will significantly boost drug design efficiency and accelerate practical applications.

CDMO Commercial Manufacturing Fuels Revenue Growth; CMC Segment Successfully Achieves Profitability

During the Reporting Period, two new CDMO commercialization projects were successfully landed. Through structural adjustment and optimization of its client portfolio, the CMC business has continuously improved project delivery rates, and has successfully achieved a turnaround from loss to profitability.

For the first half of 2026, Langhua Pharmaceutical recorded total revenue of RMB601.4 million, representing a year-on-year increase of approximately 47.0%. Adjusted gross profit totaled RMB175.1 million, up approximately 12.9% year-on-year. The revenue growth was primarily driven by two new CDMO commercialization projects. A peptide project has entered the commercial stockpiling stage, and a small-molecule project is currently at the PPQ production stage. Meanwhile, the API and the intermediates and formulations business are expected to gradually recover in the second half of the year. As of June 30, 2026, Langhua Pharmaceutical had served a cumulative total of 920 clients, with a 100.0% retention rate among its top ten customers. The current total production capacity stands at 860 cubic meters, which is sufficient to support the actual commercial production of new commercialized products over the next two years. In addition, an additional 400 cubic meters of capacity is being constructed to cater to the future volume growth of new molecule commercial production.

In 2025, the Group established a new PPO (Peptides, Proteins and Oligo Nucleotides) business unit. It is also one of the Group’s key strategic focuses for future development. The unit has already completed peptide CMC-related capabilities and team assembly. During the Reporting Period, the unit delivered 21 peptide projects accumulatively, with 19 projects currently in progress. Going forward, the PPO business unit will continue to strengthen its technological capabilities in peptides, conjugated drugs, and small nucleic acids.

Exit Proceeds to Be Deployed Towards Incubation of New Projects

During the Reporting Period, the Group realized aggregate cash proceeds of approximately RMB218.4 million from successful exits of several incubation portfolio companies over the past year and in the first half of this year. The Company plans to deploy a portion of such proceeds towards incubating new projects, leveraging its existing AI+SBDD dry-wet experimental platform. As of June 30, 2026, the Group had invested in and incubated a cumulative total of 93 start-up companies, with a cumulative total of nearly 232 pipelines under development, of which 188 are in the preclinical stage and 44 have advanced into the clinical stage. To date, the Group has achieved full or partial exits from 19 incubated companies.

Through the comprehensive upgrade of its three underlying modules, V-Scepter, V-Orb, and V-Mantle, the platform will significantly boost drug design efficiency and accelerate practical applications.

ITPS Canada Achieves NATO Flight Training Europe Accreditation

By
Advertorial Desk
-
London, Ontario – Newsfile Corp. – August 26, 2026 – ITPS Canada Ltd., together with its subsidiaries, the International Test Pilots School (ITPS) and the International Tactical Training Centre (ITTC), has achieved accreditation under NATO Flight Training Europe (NFTE), following a comprehensive evaluation of its training capabilities and operating environment.

2026 School Photo at International Test Pilots School

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9198/311371_itpsimage1.jpg

The accreditation marks an important milestone for ITPS Canada, providing independent recognition of the standards underpinning its international aerospace training operations. NATO Flight Training Europe is a multinational initiative designed to provide NATO nations with access to a network of high-quality military aviation training capabilities.

ITPS Canada’s accreditation places the organization within the NFTE framework and provides participating NATO air forces with a more direct mechanism to access accredited training delivered by ITPS and ITTC, spanning specialist flight test and aerospace training as well as advanced military flying and tactical training.

International Tactical Training Centre in North Bay, Ontario

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9198/311371_itpsimage2.jpg

“This accreditation reflects how ITPS Canada has continued to grow while remaining focused on the standards and capabilities that have earned the trust of customers around the world,” said Giorgio Clementi, Executive Chairman, ITPS Canada Ltd. “We have continued to invest in our people, aircraft, simulation, infrastructure, and training methodologies to meet increasingly complex requirements. NFTE accreditation is an important endorsement of that investment and of the professional framework we have built across ITPS and ITTC.”

The NFTE accreditation process assesses training providers against demanding criteria spanning aviation safety, training quality, governance and supervision, regulatory compliance, operational delivery, infrastructure, and duty of care. Accreditation provides customers with additional assurance that ITPS Canada’s training environments meet the standards expected for military aviation training within the NATO framework.

ITPS provides specialist flight test and aerospace training for test pilots, flight test engineers and associated specialists. ITTC, based in North Bay, Ontario, provides advanced military flying and tactical training for fighter aircrew preparing for increasingly complex operational environments.

International Test Pilots School in London, Ontario

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9198/311371_itpsimage3.jpg

Together, these capabilities represent a growing Canadian sovereign pilot training capability, expanding the capacity available within Canada to support domestic, NATO and Allied air force requirements. ITTC’s investment in advanced training capabilities, including the Leonardo M-346 Block 20 Advanced Jet Trainer, further builds Canada’s domestic training capacity while strengthening ITPS Canada’s ability to support the requirements of modern air forces.

“This accreditation recognizes the professionalism, discipline and operational focus that define both ITPS and ITTC,” said Dave Lohse, CEO, ITPS Canada. “Our teams have worked diligently to build training environments that meet the highest international standards, with safety underpinning everything we do. We are proud to support NATO and Allied partners while contributing to the readiness and interoperability required for collective defence.”

“CCC is pleased that ITPS has achieved NATO’s accreditation, a significant milestone that reflects the company’s world-class expertise, innovation, and commitment to excellence in pilot training. This recognition positions ITPS for continued growth with Canada’s allies and like-minded nations. We look forward to securing more government-to-government (G2G) contracts with ITPS to help expand the reach of their training around the world.” – Bobby Kwon, President and CEO of CCC.

As NATO and Allied air forces face growing demand for highly qualified aircrew, ITPS Canada will continue investing in its aircraft fleets, synthetic training systems, instructional capability, facilities, and people. Through ITPS and ITTC, the organization is positioned to contribute additional training capacity across the Alliance and support the operational readiness of NATO and Allied air forces.

ITPS Canada extends its appreciation to NATO Flight Training Europe and the Accreditation Team for their thorough evaluation and continued collaboration.

– 30 –
Media Contact
Sheila Hodgson
Director, Sales and Marketing
press@itpscanada.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311371

The issuer is solely responsible for the content of this announcement.

Vinhomes Strengthens Its Position at the Forefront of Smart City Development

By
Advertorial Desk
-

Project integrates UNESCO-recognized Can Gio mangrove forest as core climate infrastructure, expanding ESG to include Regeneration and Climate Adaptation


HANOI, VIETNAM – Media OutReach Newswire – 26 August 2026 – Vinhomes Green Paradise, the 2,870-hectare coastal urban development in Can Gio, has become the first greenfield project worldwide to receive the Interim Custom ISO 37122 Smart City Certification from the World Council on City Data (WCCD), even before the arrival of its first residents.

An aerial master plan of Vinhomes Green Paradise in Can Gio, the world's first greenfield project to achieve early-stage ISO 37122 Smart City Certification from the World Council on City Data.
An aerial master plan of Vinhomes Green Paradise in Can Gio, the world’s first greenfield project to achieve early-stage ISO 37122 Smart City Certification from the World Council on City Data.

The milestone reinforces Vinhomes’ pioneering “ESG++” model for the project, a framework that moves beyond traditional environmental, social and governance pillars to explicitly incorporate Regeneration and Climate Adaptation as core design principles.

By placing the adjacent UNESCO-recognized Cần Giờ Mangrove Biosphere Reserve at the center of its urban strategy, rather than treating it as peripheral landscape, Vinhomes is demonstrating that large-scale coastal development can simultaneously address biodiversity loss, carbon sequestration and long-term climate resilience.

A measured response to the global urban health crisis

The urgency of rethinking urban models is underscored by global health data. According to the Health Effects Institute’s State of Global Air 2025 report, air pollution was linked to 8.1 million deaths worldwide in 2021, overtaking tobacco to become the second-leading global risk factor for death and the leading cause of death for children under five after malnutrition. The World Health Organization estimates that approximately 89% of the 4.2 million annual premature deaths attributed to outdoor air pollution occur in low- and middle-income countries, precisely the regions experiencing the fastest urban growth.

This reality has redirected global capital flows. Grand View Research projects the global smart-city market to reach USD 3.76 trillion by 2030, compounding at nearly 30% annually, one of the fastest expansion rates across any industry sector. In this context, the question is no longer whether smart cities are worth building, but which developments can demonstrate independently verifiable performance.

Vinhomes Green Paradise has addressed this global benchmark through its Interim Custom ISO 37122 Smart City Certification, awarded by the World Council on City Data (WCCD), which validates its smart infrastructure and data-driven urban governance against international standards.

Moving beyond conventional standards, the project operates under an elevated philosophy known as ESG++, integrating two commitments that extend well past standard corporate reporting: Regeneration and Climate Adaptation. Under the pillar of Regeneration, the development goes beyond traditional conservation by actively restoring local coastal ecosystems through targeted mangrove reforestation, biodiversity preservation and community environmental education.

Concurrently, its Climate Adaptation strategy re-engineers urban infrastructure to proactively withstand long-term environmental hazards such as sea-level rise, storm surges and coastal erosion, ensuring the city is built for future resilience rather than simply reacting to present conditions.

Community perspectives reflect the broader appeal of this approach. Ho Chi Minh City-based content creator FABO Nguyen, speaking to CNBC, described his affection for the city’s dynamism alongside growing concerns about air quality and congestion. For him, and for many urban residents weighing similar trade-offs, the Vinhomes Green Paradise model offers a forward-looking alternative that does not require leaving the region, but instead redefines what a sustainable, livable urban environment can look like.

Mangrove forests as climate infrastructure

What sets Vinhomes Green Paradise apart from most coastal megaprojects globally is not merely its size, but its ecological adjacency. The development borders the Can Gio Mangrove Biosphere Reserve, a UNESCO-recognized site spanning over 75,000 hectares, one of southern Vietnam’s most valuable natural assets.

Recent scientific research has revalued the role of mangroves in climate regulation. A study published in Nature Communications indicates that while mangroves account for just 0.36% of global forest area, they sequester carbon per hectare at nearly four times the rate of mature terrestrial forests, making them among the most efficient natural carbon sinks on Earth. According to the Blue Carbon Initiative, a single hectare of mangrove forest can store carbon equivalent to approximately 1,500 tons of CO₂, a figure no concrete structure can replicate.

Against a backdrop where global mangrove cover has declined by as much as 67% in some estimates, Vinhomes has adopted a preservation-first strategy. The Vinhomes Green Paradise master plan limits building density to just 16% of the total area and establishes a dedicated Forest Regeneration and Climate Adaptation Fund. These measures treat the adjacent mangrove ecosystem not as passive scenery but as active, natural defensive infrastructure against coastal erosion and storm surges, precisely the approach that climate scientists are urging coastal cities worldwide to adopt.

This ecological commitment aligns with measurable economic value. JLL’s research across Asia Pacific, based on an analysis of nearly 3,100 Grade A office buildings in 14 cities, shows that green-certified buildings can command rental premiums as high as 28% over non-certified equivalents in the region’s tightest markets, with supply continuing to lag behind occupier demand. Sustainability, in other words, has ceased to be simply a virtue and has become a measurable asset class.

Similarly, the global energy transition reinforces the viability of Vinhomes Green Paradise’s renewable-energy targets. The Global Wind Energy Council forecasts offshore wind capacity to nearly triple from 83 GW in 2024 to approximately 238 GW by 2030, while the International Energy Agency projects global renewable capacity to grow by 4,600 GW over the same period, equivalent to adding the combined current generation capacity of China, the European Union and Japan. Against this backdrop, Vinhomes Green Paradise’s ambition to run on offshore wind, solar and battery storage reflects a broader global trajectory rather than an isolated pledge.

A blueprint for 21st-century urbanization

Taken together, the ISO 37122 certification, the ESG++ framework, the strategic integration of the Can Gio mangrove ecosystem and the economic revaluation of green assets, Vinhomes Green Paradise presents a coherent response to a defining question in contemporary real estate: how to build cities that are both worth living in and built to endure.

The project’s recognition as the first Official Participant in New7Wonders’ global “7 Wonders of Future Cities” campaign further underscores its international relevance. Vinhomes Green Paradise serves as a notable reference point for coastal urban development, illustrating how economic growth and ecological preservation can be integrated in regional contexts.

Hashtag: #Vinhomes

The issuer is solely responsible for the content of this announcement.

About Vinhomes

Vinhomes is Vietnam’s largest residential real estate and integrated township developer. The company pioneers the development of synchronized, modern large-scale townships, delivering premium living standards and unlocking sustainable investment opportunities for domestic and international clients.

Milkground and DKSH Hong Kong Announce Strategic Partnership to Bring Cheese Products to Hong Kong

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 26 August 2026 – Milkground (600882.SH), one of China’s leading cheese brands, today announced a strategic partnership with DKSH, a leading partner for companies seeking to grow their consumer goods business in Asia and beyond, to bring a wide range of cheese products to consumers in Hong Kong. The partnership was unveiled at a press conference attended by Milkground President Kuai Yulong and DKSH Vice President, FMCG, Greater China, Hugo Reyes, along with senior executives from both companies.

Milkground and DKSH Hong Kong Announce Strategic Partnership to Bring Cheese Products to Hong Kong

With over 160 years of experience helping companies grow across Asia and beyond, DKSH is headquartered in Switzerland and operates in 35 markets, working with more than 500 consumer goods companies and 4,800 business partners to connect them to extensive retail and food services networks across the region.

Hugo Reyes, DKSH Vice President, FMCG, Greater China, said: “Milkground has built a reputation in China for quality, nutrition, and innovation that few dairy brands can match. Consumer habits across Asia are shifting toward convenient and healthy snacking, trusted premium brands and family-oriented food solutions – trends that open up substantial opportunities for Milkground’s full range across multiple markets.”

The partnership will begin in Hong Kong’s retail market, with plans to expand into food services and, over time, other markets across Asia through DKSH’s regional network. For Milkground, DKSH was a natural choice: entering a new market takes more than getting products onto shelves – it takes an understanding of local tastes, strong retail relationships, and the patience to build a brand families trust over time, all strengths DKSH brings to the table.

Reyes added that Milkground, backed by Mengniu Group, brings mature industry experience, strong dairy R&D capabilities, and a solid supply chain, giving it a firm base for future category growth. As dairy consumption grows across Asia, he said the two companies see room to expand beyond cheese over time and look forward to exploring that opportunity together.

Kuai Yulong, Milkground President, said: “Hong Kong’s energy and openness to the world made it the natural place to start. Hong Kong remains one of Asia’s most dynamic and internationally connected consumer markets. For Milkground, our ambition is to become not just a leading Chinese brand, but a name recognised all over the world. Today’s launch is the first step of that journey.”

Looking ahead, Milkground outlined three priorities for its partnership with DKSH in Hong Kong:

Growing the range: From children to adults, from everyday snacking to the family table, Milkground plans to keep expanding and refining its cheese offerings, so Hong Kong consumers have more ways to enjoy quality cheese – and more households across the city can make it part of daily life.

Listening to the market: Milkground will pay close attention to how Hong Kong shoppers actually buy and use cheese. That feedback will keep shaping everything, from product updates and shelf displays to the in-store experience.

Working hand in hand with DKSH: Both companies plan to work closely, share information openly, and move quickly as they keep improving products, operations, and service together. The aim: happier retail partners and consumers, and a Milkground brand that Hong Kong trusts.

Kuai noted that Hong Kong consumers already have a strong appetite for cheese and well-established habits around it, which makes the city an easier market to enter than most. He sees it as the perfect place to test whether Milkground’s products can win over consumers used to international standards, calling it a meaningful proving ground for the brand’s broader ambitions.

Hong Kong is also central to Milkground’s plans beyond the city. Kuai Yulong outlined the company’s three-pronged roadmap for international expansion: first, use Hong Kong as the core to establish a presence across Hong Kong, Macau, Central Asia and Mongolia; second, expand into Southeast Asia, represented by Thailand, Malaysia and Singapore; and third, enter the Middle East, anchored by Saudi Arabia. To date, Milkground has already established a presence in Thailand, Singapore, Vietnam and Mongolia, and has reached a partnership agreement with a leading dairy company in Saudi Arabia.

Kuai further emphasised that overseas business is one of the wings under Mengniu Group’s “One Body, Two Wings” strategy. The group’s increasingly mature and systematic approach to overseas markets will help Mengniu’s international operations scale quickly, while leveraging its core strengths to accelerate global expansion.

Hashtag: #Milkground #DKSH

The issuer is solely responsible for the content of this announcement.

About Milkground

Milkground (Stock Code: 600882.SH) is the only A-share listed company in China focused on cheese. Controlled by Mengniu under COFCO, the company operates as a dual-brand cheese platform running both the Milkground and Mengniu Cheese brands. Headquartered in Shanghai, it operates six factories in Fengxian and Jinshan (Shanghai), Tianjin, Hohhot, Changchun, and Jilin, making it one of the mainland’s largest cheese producers.

With a global vision, Milkground has assembled an R&D team led by international experts. Backed by Mengniu Group, the company has established a Global Cheese R&D Innovation Center, and introduced world-class production equipment. The company collaborates with cheese makers from Europe and Australia to adopt advanced technologies. Using premium global ingredients and strict quality control across every step, it drives innovation throughout the supply chain to craft each cheese product with care.

Milkground’s product range includes Ready-to-Eat Nutrition, Family Cheese, and Foodservice & Industrial series. Its Cheese Sticks and Mozzarella, and Cheese Slices have become best-selling fan favorites.

Guided by a consumer-centered philosophy and craftsmanship in pursuit of excellence, Milkground is committed to making quality cheese a part of every household.

Website:

About DKSH Group

For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific, Europe, and North America across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales of CHF 11.1 billion in 2025.

DKSH Business Unit Consumer Goods focuses on fast moving consumer goods, luxury and lifestyle products, food services, as well as beauty and wellness. With 13,620 specialists, the Business Unit generated net sales of CHF 3.4 billion in 2025.

MicroBit Launches Hong Kong’s First Bitcoin and Gold ETF on HKEX Today

By
Advertorial Desk
-

Hong Kong SAR – Media OutReach Newswire – 26 August 2026 – MicroBit Capital Management Limited (“MicroBit”), a Hong Kong-based investment manager specialising in virtual assets and frontier technologies, today announced the listing of the MicroBit Bitcoin and Gold Value ETF (HKD Counter: 3002.HK; USD Counter: 9002.HK) on The Stock Exchange of Hong Kong Limited (“HKEX”).

MicroBit Group CEO (right 1) and COO (left 1) striking the Gong
MicroBit Group CEO (right 1) and COO (left 1) striking the Gong

The ETF is Hong Kong’s first to offer exposure to both bitcoin and gold, offering a diversified approach across two value asset classes.

The Fund combines bitcoin’s long-term digital-asset potential with gold’s role as a store of value, offering diversified exposure in a single ETF. Gold may help stabilize overall portfolio volatility. The ETF also supports in-kind subscriptions and redemptions in bitcoin, while in-kind bitcoin subscriptions and redemptions provide eligible market participants with added flexibility.

Wilson Fung, Chief Executive Officer of MicroBit Group, said: ” We are proud to launch Hong Kong’s first Bitcoin and Gold ETF. By combining bitcoin’s digital-asset potential with gold’s established role as a store of value, the Fund offers investors a forward-looking, diversified allocation tool. This launch marks an important milestone in MicroBit’s mission to bridge traditional finance and the Web3 ecosystem.”

MicroBit will continue to explore innovative investment solutions and is committed to providing investors with a broader range of innovative and diversified investment tools.

Important Information:

Investment involves risks. Past performance does not represent future performance. The price of the fund may go up or down. Investors may suffer all or significant investment losses. Investors should not make any investment decisions solely based on this information. Please note that the investment risks listed below are not exhaustive. Investors should carefully read the prospectus, product key factsheet and relevant documents before making any investment decisions to understand details including product characteristics, risk factors and distribution policies, and seek for independent financial advice when necessary.

MicroBit Bitcoin & Gold Value ETF (the “Sub-Fund”) is a sub-fund of MicroBit Funds Series (Hong Kong) ETF OFC (the “Company”). The investment objective of the Sub-Fund is to seek long-term capital appreciation by providing diversified exposure to both digital and traditional store-of-value assets, namely bitcoin and gold. There can be no assurance that the Sub-Fund will achieve its investment objective.

MicroBit Bitcoin & Gold Value ETF could be subject to certain key risks such as Investment risk; Active investment management risk; Risks relating to bitcoin (including Bitcoin and bitcoin industry risk, Speculative nature risk, Extremely high volatility risk, Unforeseeable risk, Acceptance of bitcoin, Concentration of ownership risk, Fraud, market manipulation and security failure risk, Cybersecurity risks, Potential manipulation of Bitcoin Network risk, Regulatory risk, Internet risk, Fork risk, Virtual Assets’ trading platform risk in general and contagion risk, Risk of illicit use, Environment and energy consumption risk, Political or economic crisis risk, etc.); Gold market risk; Futures contracts risks; Bitcoin and gold concentration risk; New product risk; Risks in relation to Virtual Asset Trading Platform(s); Custody risk; Differences in dealing arrangements between Listed and Unlisted Classes of Shares; Differences in cost mechanisms between Listed and Unlisted Classes of Shares risk; Trading risk; Trading hours differences risk; Reliance on market makers risk; Early termination risk; Multi-counter risk.

The above products have been authorized by the Securities and Futures Commission (“SFC”). Authorization by the SFC does not imply official recommendation. This material is for reference only and does not constitute an offer or suggestion of any transaction in any products.

This material is prepared by MicroBit Capital Management Limited and has not been reviewed by the SFC. If you are in any doubt about the content of this material, please refer to the prospectus, product key facts statement and other relevant documents for details, and seek for independent financial advice when necessary.

MicroBit does not guarantee the accuracy, timeliness, completeness, or reliability of the information provided. All materials are presented “as is”, without any warranties of any kind, whether express or implied, including but not limited to merchantability, fitness for a particular purpose, or non-infringement. Unless otherwise specified, some of the views and recommendations are compiled by MicroBit based on publicly available data and market experience.

Copyright © 2026 MicroBit Capital Management Limited. All rights reserved.
Hashtag: #MicroBit#Cryptocurrency#Gold#HongKong#ETF#Investment




Wechat: 小飞资产MicroBit Capital

The issuer is solely responsible for the content of this announcement.

MicroBit Capital Management Limited

MicroBit Capital Management Limited is a premier Hong Kong-based investment manager specialising in thematic investing across virtual assets and frontier technologies. We are committed to delivering innovative investment solutions to institutional investors, family offices, high-net-worth individuals, and retail investors, empowering them to diversify portfolios and capture the transformative potential of virtual assets and frontier technologies.

MicroBit is licensed by the Securities and Futures Commission of Hong Kong (SFC) for Type 1 (Dealing in Securities), Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated activities, and is subject to additional terms and conditions for Virtual Asset Fund Managers (VAFMs) imposed by the SFC (“VAFM T&Cs”). Welcome to visit our website for further details: .

Uni-Bio Science Group Announces 2026 Interim Results

By
Advertorial Desk
-

Revenue Reached HK$ 273.8M, Driven by Solid Growth from Bogutai®

Innovation-Driven Transformation Progresses with Portfolio Optimization and Broader Market Access

HONG KONG SAR – EQS Newswire – 26 August 2026 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2026 (the “Period”).

Key Accomplishments in the First Half of 2026

During the Period, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

1. During the Period, the Group’s revenue reached approximately HK$273.8 million, with net profit standing at approximately HK$31.2 million. Cash generation remained solid, with operating cash flow at approximately HK$11.4 million. Despite temporary earnings compression resulting from regulatory adjustments and front-loaded investments in R&D, commercialization, and international expansion, the Group demonstrated operational resilience by remaining profitable and financially strong.

2. As at 30 June 2026, total equity increased by 8.6% to approximately HK$448.7 million, reflecting a strengthened capital base. The debt-to-equity ratio improved to 34.9%, demonstrating active deleveraging and prudent capital stewardship. The Group remains in a net cash positive position, with a cash ratio well above 1, indicating that cash and cash equivalents significantly exceed near-term liabilities. This strong liquidity cushion enables the Group to comfortably absorb the temporary reduction in net profit during the Period without compromising its financial stability. Together, these strengths position the Group to support future R&D investment, commercialization initiatives, and international expansion.

3. Revenue of Bogutai® increased significantly by 39.3% year-on-year (“YoY”), driven by the ongoing market development and engagement with this innovative osteoporosis therapy within the medical community and among patients in China. As of the first quarter of 2026, Bogutai® ranked second in overall market share and first in the retail channel among teriparatide products in China. Its nationwide sales surpassing those of the originator brand, achieving these market positions within approximately two years of commercial launch.

4. During the Period, the Group officially commenced the commercial launch and market promotion of its high-end series, GeneQueens®, further enriching its portfolio in functional skincare and post-procedure medical aesthetics. The premium line incorporates a proprietary triple-protein complex (Fibronectin, Type III Collagen, and Type XVII Collagen), each formatted at a high concentration of 1,000 ppm to optimize cellular repair and anti-aging performance. This milestone demonstrates concrete progress in accelerating the commercialization of its synthetic biology platform.

5. The Group is advancing the development of its BMP-2 regenerative medicine program. Utilizing its proprietary ECO-KSFA® platform, the Group has successfully established a high-yield production process for BMP-2 API, a crucial growth factor in regenerative medicine widely applied in spinal fusion and bone defect reconstruction. During the Period, the Group completed pilot-scale manufacturing process for the BMP-2 drug substance and initiated development of a sustained-release gel formulation, laying a solid foundation for finalizing the product’s clinical dosage form.

6. The next-generation generic antifungal drug, Isavuconazonium sulfate capsules, completed all supplementary studies required by the regulator and the Group is preparing to submit the corresponding documentation to the Center for Drug Evaluation (CDE) in the second half of 2026. To support future commercialization, the Group has commissioned a dedicated production line specifically designed for the product and established strategic partnerships with high-quality API suppliers to ensure reliable manufacturing capacity and supply for commercialization.

Interim Results

The first half of 2026 marked a strategic transition period for the Group, characterized by portfolio optimization alongside expanding channel and market access. Revenue during the Period was temporarily impacted by strategic volume-based procurement (VBP) pricing adjustments for Pinup® and, to a lesser extent, GeneTime®, coupled with the structural impact of latest biologics value-added tax (VAT) policies on net selling price. For the Period, the Group recorded revenue of approximately HK$273.8 million, representing a decrease of 11.7% YoY.

Revenue of Bogutai® increased significantly from approximately HK$65.6 million to approximately HK$91.4 million, representing an increase of 39.3%. Revenue of Boshutai® increased by 50.8% from approximately HK$6.1 million to approximately HK$9.2 million. GeneTime® recorded a decrease of 12.3% in revenue from approximately HK$107.8 million to approximately HK$94.5 million. Sales volume of GeneTime® achieved high-single-digit YoY growth, reflecting continued strong underlying demand and the initial benefits of broader hospital access and prescription-base expansion. GeneSoft® recorded a 1.6% YoY increase in revenue from approximately HK$18.5 million to approximately HK$18.8 million. Pinup® recorded a decrease of 47.1% in revenue from approximately HK$108.9 million to approximately HK$57.6 million. With a limited number of product portfolio and the ongoing optimization of its marketing and distribution teams, revenue from 肌顏態® increased from approximately HK$1.3 million to approximately HK$2.2 million, representing a 69.2% YoY growth. Revenue contribution from the Group’s newly launched medical device product 金因敷® and 金因康® (Diquafosol Sodium Eye Drops) were immaterial during the Period. The Group is expanding its digital and social media presence to raise 金因敷® brand awareness, while advancing targeted non-public channel expansion to accelerate 金因康® uptake.

Gross profit was approximately HK$222.7 million, representing a decrease of 12.4% as compared with approximately HK$254.1 million for the first half of 2025, whereas as gross profit margin remained stable at 81.3%. Profit for the Period decreased by 59.0% YoY to approximately HK$31.2 million. The decrease primarily reflected short-term profitability pressure during the Group’s strategic transformation, including lower absolute gross profit resulting from pricing adjustments for certain core products and the VAT-related pricing impact, together with continued investment in commercialization, new product launches, pipeline development, and international expansion. The earnings per share were approximately HK$0.52 cents, compared with HK$1.27 cents in the first half of 2025.

Prospects

Through targeted commercial and R&D investments in the first half of 2026, the Group enters the second half well positioned to accelerate its business transformation. As generic therapies continue to yield ground to higher-margin biopharmaceuticals within the Group’s portfolio, this evolving revenue mix is expected to deliver sustained margin expansion over the long term. With biopharmaceuticals recognized for the first time as an emerging pillar industry supported by the state, the Group is committed to growing its innovation capabilities and expanding its commercial reach to capture this growing market opportunity.

Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented, “The first half of 2026 presented a challenging operating environment, which we view as a transitional period toward a more diversified and all-round range of product offerings and promotional channels. During the period, we made significant progress in strengthening both the breadth and depth of our commercial platform while advancing a robust pipeline of innovative therapies. Our omni-channel strategy, spanning public hospitals, an expanding distributor network, retail pharmacy locations, and leading e-commerce platforms, continues to broaden patient access across China, including deeper penetration into Tier-3 and Tier-4 cities. At the same time, we are executing a disciplined, product-specific commercialization approach, tailoring our strategies to the distinct market dynamics of each of our eight core products. Beyond our domestic base, we are accelerating our global ambitions. We are advancing Bogutai®’s international expansion, together with our ongoing U.S. FDA submission, an important step toward establishing our first overseas commercialized therapy.

Our pipeline continues to advance meaningfully, from our proprietary EGF/FGF compound gel for wound care to next-generation BFS-based GeneSoft® formulations and our BMP-2 regenerative therapy, all underpinned by our proprietary ECO-KSFA® synthetic biology and Biological Hydrogel technology platforms. These innovation engines position us to continue delivering differentiated, high-value therapies across pharmaceuticals, medical devices, and medical aesthetics. We remain confident that our integrated strategy, combining commercial excellence, global expansion, and platform-driven innovation, will create sustainable long-term value for our patients, partners, and shareholders.”

Hashtag: #Uni-BioScienceGroup

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001 (Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to be the global leader in regenerative medicine, redefining how science restores and extends human life.

For further information, please contact: ir@uni-bioscience.com

PolyU x BOCHK International Future Challenge (Hong Kong Regional Final) yields top four teams, 18 innovative teams showcase capabilities at Global Unicorn Summit

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 26 August 2026 – Hosted by The Hong Kong Polytechnic University (PolyU) and title sponsored by Bank of China (Hong Kong) (BOCHK), the PolyU x BOCHK International Future Challenge (Hong Kong Regional Final) concluded earlier (24 August) at the Hong Kong Convention and Exhibition Centre. Featured on the main stage during the Global Unicorn Summit (the Summit), organised by the Hong Kong Ta Kung Wen Wei Media Group, 18 top Challenge startup teams, selected from over 300 entries, showcased their strengths competing for various awards and the top four spots which advance to the Grand Final. Prof. Jin-Guang TENG, PolyU President, meanwhile delivered a keynote speech at the Summit themed “How University Research Empowers Industrial Innovation”. He elaborated on the mission and characteristics of university research, and shared PolyU’s successful experience in driving research translation through the establishment of Mainland Translational Research Institutes.

VIP guests, members of the judging panel, and winning teams pose for a group photo on stage.
VIP guests, members of the judging panel, and winning teams pose for a group photo on stage.

Following its title sponsorship of the inaugural PolyU x BOCHK International Future Challenge Grand Final, BOCHK demonstrated its continued support this year as the title sponsor for both the Hong Kong Regional Final and the Grand Final of the PolyU International Future Challenge (PolyU IFC) 2026, joining hands with PolyU to nurture young innovation and technology (I&T) talents and drive high-quality development in the innovation and entrepreneurship ecosystem.

The Hong Kong Regional Final focused on five cutting-edge fields: Life Sciences and Healthcare, Advanced Manufacturing and Microelectronics, Digital Economy and Financial Technology, Smart City and Green Living, as well as Aerospace and Aviation Technology. The Hong Kong region competition generated an enthusiastic response, fully demonstrating Hong Kong’s vitality and appeal as an international I&T hub. The 18 shortlisted teams made on-site pitches and exhibited at the exhibition zone of the Summit, presenting their innovations to visitors, investors, and industry leaders.

Prof. Zijian ZHENG, PolyU Vice President (Knowledge Transfer), remarked, “With Hong Kong serving as a super-connector, PolyU IFC 2026 successfully builds a cross-regional platform that closely connects the Chinese Mainland, the Middle East and beyond, creating unprecedented opportunities for global innovation and collaboration. We are delighted to see 18 outstanding startup teams showcase their innovative solutions. These projects are a testament to the vision, perseverance and collaborative spirit that define the PolyU mission as an innovative world-class university. PolyU’s unique startup ecosystem, PolyVentures, boasts over 900 active startups, including unicorns and listed companies. We look forward to today’s teams leveraging this platform to step onto a broader entrepreneurial stage.”

The Hon Ken LEE, Advisor to BOCHK and Legislative Council Member, stated in the speech, “BOCHK is pleased to once again support PolyU’s flagship innovation competition, joining hands to build a supportive ecosystem that nurtures innovation and technology talent. By accelerating the practical application of innovative ideas and research achievements, this initiative aligns closely with national strategies and HKSAR Government policies, supporting Hong Kong’s development into an international innovation and technology hub.”

Prof. Christopher CHAO, PolyU Senior Vice President (Research and Innovation), Prof. Cheng DONG, PolyU Associate Vice President (Knowledge Transfer) and Mr Marston WONG, Deputy General Manager of Commercial Banking Departmentof BOCHK presented the top four awards. Following rigorous evaluation by the judging panel and on-site voting, 11 winning teams were selected. The top four teams from the Hong Kong Regional Final advance to the Grand Final held in Hong Kong in January next year, to compete with winners from other regions for the highest honours.

The winning teams from the Hong Kong Regional Final are as follows:

Award Team/Company Project Cash Prize
BOCHK Diamond Cup CobotAI Limited TeleX: Industrial Embodied Multi-Modal Data Intelligent Collection Terminal and Skill Platform HK$120,000
Gold Award LI Shuai
CHENG Lok Kan SUN Yu
LEE Ka Sing
SONG Zhen
HU Zengbo 		Novel BCI Interaction Technology Based on Multi-dimensional Sonomyography (SMG) Signals HK$75,000
Silver Award AniMed Technology Limited OptiFi Sleep HK$50,000
Bronze Award Motomics Limited MotusAI — Physics-Aware Biomechanical Agent for Musculoskeletal Disorder Assessment HK$25,000
Best Student Team Award LIO Kun Hon
CHEN Tak Hei
KUONG Ka I
CHAN Kuan Ieong
CHAN Cheng Tong KARUMANCHI Abhishikth 		PulmoSight HK$25,000
Best Presentation Award OnAn Technology Service Limited Company OnAn Technology HK$5,000
Best Presentation Award Visorx Technology Limited Visor™ RECURE DEVICE HK$5,000
Best Innovation Award LI Shuai
CHENG Lok Kan SUN Yu
LEE Ka Sing
SONG Zhen
HU Zengbo 		Novel BCI Interaction Technology Based on Multi-dimensional Sonomyography (SMG) Signals HK$5,000
Best Innovation Award Easenory Technology Limited World-Leading Elastic Textile PCB HK$5,000
Most Popular Award Bondcare Tech (Hong Kong) Limited Bondcare-Canxiao Intelligent State-based Clinical Care HK$5,000
Most Popular Award Stairio Limited Stairio HK$5,000

As the University’s flagship innovation and entrepreneurship competition, PolyU IFC is strategically aligned with the Nation’s 15th Five-Year Plan and “Artificial Intelligence (AI)+” initiative. This year, an overseas region was introduced for the first time, meaning the inclusion of nine competition regions in total: Hong Kong, Qianhai, Wuhan, Nanjing, Jinjiang, Hefei, Hangzhou, Wuxi and Saudi Arabia. Leveraging the crossborder network of the PolyU Mainland Translational Research Institutes and in collaboration with local government authorities and leading enterprises, the Challenge focuses on “AI+” to foster precise alignment between research projects and regional industrial resources.

To date, over 1,400 competition applications have been received from across the nine competition regions. Registration for the Jinjiang, Hefei, Hangzhou and Wuxi regions is currently open. For further details, please visit the official PolyU IFC website.

Hashtag: #PolyU #BOCHK #GlobalUnicornSummit

The issuer is solely responsible for the content of this announcement.

Eddid Financial Appointed as Participating Dealer for MicroBit Bitcoin and Gold Value ETF

By
Advertorial Desk
-

Supporting Innovative Cross-Asset Architecture to Advance Hong Kong’s Digital Asset Infrastructure

HONG KONG, Aug. 26, 2026 /PRNewswire/ — Eddid Financial (“the Group”), a comprehensive financial services group, announced that its subsidiary, Eddid Securities and Futures Limited, has been appointed as a Participating Dealer for the MicroBit Bitcoin and Gold Value ETF (3002.HK / 9002.HK). The ETF officially commenced trading on the Main Board of the Stock Exchange of Hong Kong today.

As a core Participating Dealer, Eddid Financial will utilize its advanced trading infrastructure and institutional-grade market-making capabilities to provide primary market in-kind and in-cash subscription and redemption services. The Group is committed to offer investors with seamless access to diversified asset allocation channels.

Innovative Cross-Asset Structure Delivers Enhanced Portfolio Resilience

The MicroBit Bitcoin and Gold Value ETF combines the two major asset classes, digital and traditional, and delivers an innovative cross-asset allocation tool to the market. Both Bitcoin and gold exhibit low long-term correlation with other traditional assets, which helps enhance investment resilience and supports diversification. Adding gold to the portfolio elevates the product’s safe-haven attributes, effectively reducing overall portfolio volatility. From an asset management perspective, the fund features a periodic rebalancing mechanism to adjust portfolio holdings on a regular basis, maintaining the allocation of Bitcoin and gold at target proportions.

Strategic Digital Asset Expansion Solidifies Hong Kong’s Web3 Financial Hub Position

While innovative, the dual-asset nature of the product places extremely high demands on the subscription and redemption mechanisms and technical integration. However, with its virtual asset licensing compliance framework and multi-asset settlement capabilities, Eddid Financial has successfully built an efficient in-kind and in-cash subscription and redemption mechanism for the ETF, demonstrating the Group’s comprehensive strength in handling complex financial products.

Since the first launch of virtual asset spot ETFs in Hong Kong, the Group has consistently been a Participating Dealer for multiple mainstream issuers covering all Bitcoin, Ethereum, Solana, and multi-asset themed spot ETFs in the market, supporting in-kind and in-cash subscription and redemption mechanisms of the relevant products. Dr. Ricky Yeung, Head of the Virtual Asset Department at Eddid Financial, states: “We are very pleased to be appointed as a Participating Dealer for this innovative ETF to provide clients with seamless solutions that bridge traditional and digital assets. Eddid Financial will continue to leverage its advantages in financial technology and compliance frameworks, cooperate closely with leading issuing institutions, and build a secure, convenient, and compliant digital asset investment bridge for institutional and individual investors.”

About Eddid Financial:

Anchored in Hong Kong, Eddid Financial is an all-encompassing financial group centered around fintech and dedicated to integrating latest technologies into its enterprise DNA. The diversified businesses of Eddid Financial range from retail to institutional and include but are not limited to fintech, internet finance, wealth management, asset management, investment banking, and digital assets. Eddid Financial is committed to providing one-stop financial services and products to customers through high-quality investment solutions. Members of the Group hold a variety of licenses and memberships across key financial markets. These include Hong Kong Securities and Futures Commission (SFC) regulated activities (“RA”) licenses for types 1, 2, 3, 4, 5, 6, and 9; SEHK and HKCC participant (OTP-C broker number: 0974 and 0977), Insurance Broker Company license; Trust or Company Service Provider License in Hong Kong. Additionally, our fully owned U.S. broker-dealer subsidiary, Eddid Securities USA Inc., maintains approved membership with the Financial Industry Regulatory Authority (FINRA), the National Futures Association (NFA), the Securities Investor Protection Corporation (SIPC), the Nasdaq Stock Market LLC (NQX), the New York Stock Exchange (NYSE) and NYSE American, and is a registered with the U.S. Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC) in the United States. Our Singapore subsidiary, Eddid Financial Singapore Pte. Ltd., holds the Capital Markets Services License (License No.: CMS101839) issued by the Monetary Authority of Singapore (MAS).

1...156157158...6,610Page 157 of 6,610